ArticleJAMA2014
Glycated hemoglobin measurement and prediction of cardiovascular disease.
Article in JAMA, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- The role of estimated glucose disposal rate in predicting cardiovascular risk among general and diabetes mellitus population: a systematic review and meta-analysis.BMC medicine · 2025Pooled it
- [Cardiovascular preventive recommendations. PAPPS 2024 thematic updates].Atencion primaria · 2024Guideline
- Pooled it
- Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2018Pooled it
- Guideline
- Olive oil in the prevention and management of type 2 diabetes mellitus: a systematic review and meta-analysis of cohort studies and intervention trials.Nutrition & diabetes · 2017Pooled it
- Pooled it
- Pooled it
- Glycemic Markers and Cardiometabolic Multiple Long-Term Conditions: Comparative Roles of Glycated Hemoglobin and Fasting Plasma Glucose in the English Longitudinal Study of Ageing.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Unraveling the Metabolic-Cardiovascular Disease Nexus: An Epidemiological Network Analysis Identifies Central Indicators.MedComm · 2026Article
- Prediabetes, obesity and risk for incident atherosclerotic cardiovascular disease: A large-scale contemporary cohort study.American journal of preventive cardiology · 2026Article
- The predictive value of glycated albumin and hemoglobin A1c for all-cause and cardiovascular mortality in chronic kidney disease patients.Diabetology & metabolic syndrome · 2026Article
- Diabetes duration, glycemic control, and risk of stroke and stroke subtypes: a nationwide prospective cohort study.Scientific reports · 2025Article
- Interplay of glycated hemoglobin and traditional risk factors for the risk of atherosclerotic cardiovascular disease and all-cause mortality in people without diabetes.Cardiovascular diabetology · 2025Observational
- Relationship between hemoglobin glycation index and myocardial mechano-energetic efficiency in non-diabetic individual.Cardiovascular diabetology · 2025Article
- Development and validation of a predictive model for carotid atherosclerosis in postmenopausal women.Scientific reports · 2025Article
- Baseline Fasting Glucose Level, Age, Sex, and Body Mass Index and the Development of Diabetes in US Adults.JAMA network open · 2025Article
- Fibrinogen glycosylation and glycation: molecular insights into thrombosis and vascular disease.Frontiers in molecular biosciences · 2025Review
- Dietary potassium intake and its interaction with sodium intake on risk of developing cardiovascular disease in persons with type 2 diabetes: The Japan Diabetes Complication and its Prevention Prospective study (JDCP study 12).Diabetes, obesity & metabolism · 2025Article
- Prospective cohort studies underscore the association of abnormal glycemic measures with all-cause and cause-specific mortalities.iScience · 2024Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
76 authors.
Funding
Abstract
importanceThe value of measuring levels of glycated hemoglobin (HbA1c) for the prediction of first cardiovascular events is uncertain.
objectiveTo determine whether adding information on HbA1c values to conventional cardiovascular risk factors is associated with improvement in prediction of cardiovascular disease (CVD) risk. DESIGN, SETTING, AND
participantsAnalysis of individual-participant data available from 73 prospective studies involving 294,998 participants without a known history of diabetes mellitus or CVD at the baseline assessment. MAIN OUTCOMES AND MEASURES: Measures of risk discrimination for CVD outcomes (eg, C-index) and reclassification (eg, net reclassification improvement) of participants across predicted 10-year risk categories of low (<5%), intermediate (5% to <7.5%), and high (≥ 7.5%) risk.
resultsDuring a median follow-up of 9.9 (interquartile range, 7.6-13.2) years, 20,840 incident fatal and nonfatal CVD outcomes (13,237 coronary heart disease and 7603 stroke outcomes) were recorded. In analyses adjusted for several conventional cardiovascular risk factors, there was an approximately J-shaped association between HbA1c values and CVD risk. The association between HbA1c values and CVD risk changed only slightly after adjustment for total cholesterol and triglyceride concentrations or estimated glomerular filtration rate, but this association attenuated somewhat after adjustment for concentrations of high-density lipoprotein cholesterol and C-reactive protein. The C-index for a CVD risk prediction model containing conventional cardiovascular risk factors alone was 0.7434 (95% CI, 0.7350 to 0.7517). The addition of information on HbA1c was associated with a C-index change of 0.0018 (0.0003 to 0.0033) and a net reclassification improvement of 0.42 (-0.63 to 1.48) for the categories of predicted 10-year CVD risk. The improvement provided by HbA1c assessment in prediction of CVD risk was equal to or better than estimated improvements for measurement of fasting, random, or postload plasma glucose levels. CONCLUSIONS AND RELEVANCE: In a study of individuals without known CVD or diabetes, additional assessment of HbA1c values in the context of CVD risk assessment provided little incremental benefit for prediction of CVD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.